Just - Evotec Biologics
401 Terry Avenue North
About Just - Evotec Biologics
Just - Evotec Biologics, is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Learn more at www.just.bio.
36 articles about Just - Evotec Biologics
Evotec SE announced its financial results and corporate updates for the first half-year of 2023.
Evotec SE announces that it is adjusting its guidance for the fiscal year 2023.
Evotec SE announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement.
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody -based drug product prototypes targeting orthopoxviruses.
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Evotec SE announced that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases.
Evotec SE presents an update on the Company's sustainability strategy and shares details on its ESG performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day.
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Evotec SE announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
Evotec SE and Sandoz AG, a division of Novartis announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer.
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Sernova Corp. announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase 1/2 clinical trial of Evotec SE’s iPSC-derived ILCs in combination with Sernova’s implantable Cell Pouch device for the treatment of patients with T1D.
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
Evotec SE reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.
Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016.
Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis.
Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
Evotec SE and the European Investment Bank announced that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company's R&D activities, equity investments and the building of the new J.POD ® biologics manufacturing facility on Evotec's Campus Curie in Toulouse, France.
Evotec SE announced that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences, to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec's industry-leading capabilities across the full R&D continuum.
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
Evotec SE presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
Evotec SE announced that the Company has entered a partnership with Hannover Medical School, one of the leading German universities, to generate a molecular patient database for Sjögren's syndrome and systemic lupus erythematosus.